ImmunoGen (IMGN) Says IND for IMGN853 Now Active
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Join SI Premium – FREE
ImmunoGen, Inc. (Nasdaq: IMGN), announced that the Investigational New Drug (IND) application for its IMGN853 product candidate is now active. IMGN853 is a potential new therapeutic for ovarian cancer, NSCLC, and other epithelial malignancies which over-express FOLR1. The Company expects Phase I evaluation of IMGN853 to begin in mid-2012.
Recently the Company announced the start of Phase II testing with its IMGN901 compound in small-cell lung cancer and – earlier today – it announced the start of Phase I testing with its IMGN529 compound in non-Hodgkin’s lymphoma. All three product candidates utilize the Company’s Targeted Antibody Payload (TAP) technology with ImmunoGen antibodies and are wholly owned by the Company.
Recently the Company announced the start of Phase II testing with its IMGN901 compound in small-cell lung cancer and – earlier today – it announced the start of Phase I testing with its IMGN529 compound in non-Hodgkin’s lymphoma. All three product candidates utilize the Company’s Targeted Antibody Payload (TAP) technology with ImmunoGen antibodies and are wholly owned by the Company.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Sigma Lithium resumes full operations after signing TAC agreement
- Solowin Holdings marks 10 years, expands into stablecoins and AI
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
